Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
latanoprost-eluting contact lens
- Development stage
- Unknown
- Lead developer
- TherOptix
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
The latanoprost-eluting contact lens is a novel drug delivery system developed by the Massachusetts Eye and Ear Infirmary in collaboration with Harvard Medical School, Boston Children's Hospital, and the Massachusetts Institute of Technology. Designed to treat glaucoma and ocular hypertension, the device consists of latanoprost-poly(lactic-co-glycolic acid) (PLGA) films encapsulated within a methafilcon hydrogel contact lens using ultraviolet light polymerization. This platform provides sustained release of latanoprost, a prostaglandin F2α receptor agonist, for up to one month. By replacing daily eye drops with a continuous-wear lens, the technology aims to significantly improve patient adherence and therapeutic outcomes. Preclinical studies in rabbits and monkeys demonstrated efficacy, and a Phase 1 clinical trial (NCT04500574) has been conducted to evaluate its safety and intraocular pressure-lowering capabilities in humans.
- Other names
- Latanoprost Eluting Contact LensLatanoprost-PLGA contact lensContact Lens Drug Delivery System with latanoprost
02
Targets
PTGER1 (Prostaglandin E Receptor 1)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on latanoprost-eluting contact lens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on latanoprost-eluting contact lens.